Expects foreign currency exchange to have negative impact of $55M based on currency rates as of January 31, 2025; Labs business growth expected in the mid-single digits; Transfusion Medicine business growth, excluding U.S. Donor Screening, in the low-single digits; Point of Care business growth, excluding COVID-19, in the mid-single-digits; China regional growth in the mid- to high-single-digits.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.